Speedy OK of Alzheimer’s drug creates a big mess for patients and taxpayers
By EsqSocial Corporation 16/06/21
The federal Food and Drug Administration has created an instant medical and regulatory morass by giving an accelerated approval to Biogen’s costly prescription medication targeted at patients with Alzheimer’s disease. This is the first drug to win the precious official nod from the FDA in almost two decades....
By: Patrick Malone & Associates P.C. | DC Injury